Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N- methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride)

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 955-967

  Midgley, Ian ^a   Fitzpatrick, Karen ^a   Taylor, Lynne M ^a   Houchen, Tara L ^a   Henderson, Simon J ^a   Wright, Sarah J ^a   Cybulski, Zbigniew R ^a   John, Brian A ^a   McBurney, Alan ^a   Boykin, David W ^b   Trendler, Kerri L ^c,d  

^a HUNTINGDON LIFE SCIENCES   (United Kingdom)

^b GEORGIA STATE UNIVERSITY   (United States)

^c Northwest Toxicology Inc   (United States)

^d NPS Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 BIS(4 AMIDINOPHENYL)FURAN; 2,5 BIS(4 GUANYLPHENYL)FURAN DIHYDROCHLORIDE; 2,5 BIS[4 (N METHOXYAMIDINO)PHENYL]FURAN MONOMALEATE; DB 289; FURAMIDINE DIHYDROCHLORIDE; PAFURAMIDINE MALEATE; PENTAMIDINE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE SECRETION; CONTROLLED STUDY; DEMETHYLATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER BLOOD FLOW; MALARIA; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA PROTEIN BINDING; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; BENZAMIDINES; BILE; BIOTRANSFORMATION; BLOOD PROTEINS; FECES; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MICE; MILK; PREGNANCY; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA; PNEUMOCYSTIS CARINII; RATTUS;

EID: 34249037167     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013391     Document Type: Article

References (28)

1. Barrett MP (1999) The fall and rise of sleeping sickness. Lancet 353:1113-1114.
2. Berger BJ, Hall JE, and Tidwell RR (1990a) The distribution of multiple doses of pentamidine in rats. Pharmacol Toxicol 66:234-236.
3. Berger BJ, Lombardy RJ, Marbury GD, Bell CA, Dykstra CC, Hall JE, and Tidwell RR (1990b) Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob Agents Chemother 34:1678-1684.
4. Berger BJ, Naiman NA, Hall JE, Peggins J, Brewer TG, and Tidwell RR (1992) Primary and secondary metabolism of pentamidine by rats. Antimicrob Agents Chemother 36:1825-1831.
5. Berger BJ, Reddy VV, Le ST, Lombardy RJ, Hall JE, and Tidwell RR (1991) Hydroxylation of pentamidine by rat liver microsomes. J Pharmacol Exp Ther 256:883-889.
6. Boykin DW, Kumar A, Hall JE, Bender BC, and Tidwell RR (1996) Anti-Pneumocystis carinii activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg Med Chem 6:3017-3020.
7. Boykin DW, Kumar A, Xiao G, Wilson WD, Bender BC, McCurdy DR, Hall JE, and Tidwell RR (1998) 2,5-[4-(N-Alkylamidino)phenyl]furans as anti-Pneumocystis carinii agents. J Med Chem 41:124-129.
8. Clement B, Immel M, and Raether W (1992) Metabolic N-hydroxylation of diminazene in vitro. Arzneim-Forsch 42:1497-1504.
9. Clement BJ and Jung F (1994) N-Hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Possible relationship to the biological oxidation of arginine to NG-hydroxyarginine, citrulline, and nitric oxide. Drug Metab Dispos 22:486-497.
10. Das BP and Boykin DW (1977) Synthesis and antiprotozoal activity of 2,5-bis(guanylphenyl)-furans. J Med Chem 20:531-536.
11. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
12. Dobrinska MR (1989) Enterohepatic circulation of drugs. J Clin Pharmacol 29:577-580.
13. Ginsburg H, Krugliak M, Eidelman O, and Cabantchik ZI (1983) New permeability pathways induced in membranes of Plasmodium falciparum infected erythrocytes. Mol Biochem Parasitol 8:177-190.
14. Guerrant RL (1999) Tropical Infectious Diseases - Principles, Pathogens and Practice. Churchill Livingstone, Philadelphia.
15. Ings RMJ (1984) The melanin binding of drugs and its implications. Drug Metab Rev 15:1183-1212.
16. Legraverend C, Mode A, Westin S, Strom A, Eguchi H, Zaphiropoulos PG, and Gustafsson JA (1992) Transcriptional regulation of rat P-450 2C gene subfamily members by the sexually dimorphic pattern of growth hormone secretion. Mol Endocrinol 6:259-266.
17. Lin JH, Chiba M, Chen IW, Nishime IW, and Vastag KJ (1996) Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. Drug Metab Dispos 24:1298-1306.
18. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
19. 14C]ximoprofen in rats, baboons, and humans. Xenobiotica 20:233-246.
20. Sherwin IR (1998) Malaria: Parasite Biology, Pathogenesis, and Protection. ASM Press, Washington DC.
21. Stead AMW, Bray PG, Edwards IG, Dekoning HP, Elford BC, Stocks PA, and Ward SA (2001) Diamidine compounds: selective uptake and targeting in Plasmodium falciparum. Mol Pharmacol 59:1298-1306.
22. Thompson KL, Vincen SH, Miller RR, Colletti AE, Alvaro RF, Wallace MA, Feeney WP, and Chiu SH (1997) Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Drug Metab Dispos 25:1113-1118.
23. Trendler KL, Allen JL, Hall JE, Stephens CE, Reuschel SA, Eagle GM, and Bennett PK (2000) Quantification of the prodrug DB289 and an active metabolite, DB75, in rat and monkey plasma using SPE, liquid chromatography and electrospray ionization tandem mass spectrometry. AAPS PharmSci 2 (2):Abstract 2212.
24. Ullberg S and Larsson B (1981) Whole-body autoradiography, in Progress in Drug Metabolism, vol 6 (Bridges JW and Chasseaud LF eds) pp 249-289, John Wiley & Sons Ltd., Chichester, UK.
25. Walzer PD (2000) Pneumocystis carinii, in Mandell, Douglas and Bennett's Principles and Practices of Infectious Diseases (Mandell GL and Dolin R eds) pp 2781-2795.
26. Wang MZ, Saulter JY, Usuki E, Cheung Y-L, Hall M, Bridges AS, Loewen G, Parkinson OT, Stephens CE, Allen JL, et al. (2006) CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O- methylamidoxime]. Drug Metab Dispos 34:1985-1994.
27. Waxman DJ, Ram PA, Notani G, Leblanc GA, Alberta JA, Morrissey JJ, and Sundseth SS (1990) Pituitary regulation of the male-specific steroid 6β-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxine acting at a pretranslational level. Mol Endocrinol 4:447-454.
28. Zhou L, Thakker DR, Voyksner RD, Anbazhagan M, Boykin DW, Hall JE, and Tidwell RR (2004) Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)furanbis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 39:351-360.